The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

President Trump’s administration has slammed the brakes on development of messenger RNA (mRNA) vaccines, which proved their ...

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...

US Health Secretary Robert F. Kennedy Jr.'s dismissal of a key panel that advises on immunizations policy is a significant ...